Table 1.
Ovarian and tubal cancers grouped by primary site and screening status
| Total | Screen positives |
Cancers not detected by screening |
|||||
|---|---|---|---|---|---|---|---|
| Screen negatives ≤1 year from last test of screening episode | Screen negatives >1 year after last test of screening episode | Never attended screening | Diagnosed >1 year after end of screening* | ||||
| Multimodal screening (50 625 women, 789 129 women-years) | |||||||
| Ovarian and tubal cancer | 522 (100%) | 212 (41%) | 41 (8%) | 41 (8%) | 3 (1%) | 225 (43%) | |
| Non-epithelial ovarian cancer | 16 (100%) | 7 (44%) | 2 (13%) | 2 (13%) | 0 | 5 (31%) | |
| Borderline epithelial ovarian cancer | 54 (100%) | 24 (44%) | 10 (19%) | 5 (9%) | 0 | 15 (28%) | |
| Invasive epithelial ovarian and tubal cancer | 452 (100%) | 181 (40%) | 29 (6%) | 34 (8%) | 3 (1%) | 205 (45%) | |
| Ultrasound screening (50 623 women, 790 231 women-years) | |||||||
| Ovarian and tubal cancer | 517 (100%) | 164 (32%) | 63 (12%) | 50 (10%) | 19 (4%) | 221 (43%) | |
| Non-epithelial ovarian cancer | 13 (100%) | 11 (85%) | 0 | 1 (8%) | 0 | 1 (8%) | |
| Borderline epithelial ovarian cancer | 59 (100%) | 48 (81%) | 2 (3%) | 1 (2%) | 3 (5%) | 5 (8%) | |
| Invasive epithelial ovarian and tubal cancer | 445 (100%) | 105 (24%) | 61 (14%) | 48 (11%) | 16 (4%) | 215 (48%) | |
| No screening (101 314 women, 1 577 517 women-years) | |||||||
| Ovarian and tubal cancer | 1016† (100%) | .. | .. | 514 (51%) | .. | 499 (49%) | |
| Non-epithelial ovarian cancer | 17 (100%) | .. | .. | 7 (41%) | .. | 10 (59%) | |
| Borderline epithelial ovarian cancer | 91 (100%) | .. | .. | 50 (55%) | .. | 41 (45%) | |
| Invasive epithelial ovarian and tubal cancer | 905 (100%) | .. | .. | 457 (50%) | .. | 448 (50%) | |
Data are n (%).
*
Screening end Dec 31, 2011.
†
Includes one case in which histology was not available and two cases of neoplasm of uncertain or unknown behaviour.